Avalo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing therapies for immune-mediated inflammatory diseases and rare genetic disorders. The company's pipeline is anchored by its lead asset, abdakibart (AVTX-009), a humanized monoclonal antibody that binds to interleukin-1β (IL-1β) and is currently in Phase 2 clinical trials for the treatment of hidradenitis suppurativa (HS). Avalo's broader portfolio has historically included other targeted therapies, such as AVTX-002 (an anti-LIGHT monoclonal antibody) and AVTX-008 (a BTLA agonist fusion protein), aimed at addressing significant unmet medical needs in immunology. Originally incorporated as Cerecor Inc. in 2011, the company rebranded to Avalo Therapeutics in 2021. The firm operates primarily in the United States and generates value through the clinical advancement of its proprietary biologic drug candidates.
